Base-promoted diastereoselective addition of nitromethane and nitroethane to N-tert-butylsulfinyl imines: synthesis of N-protected α-amino acids and amino ketones
The stereoselective synthesis of syn-β-amino propargylic ethers by the addition of racemic lithio 3-(methoxymethoxy)allenylcuprates, and more particularly (cyano) and (mesityl)cuprates, to enantiopure chiral N-tert-butylsulfinylimines is reported. The scope and limitations of the reaction is studied. The usefulness of the methodology for the synthesis of compounds having a syn-1,2-amino alcohol unit
Reversal Diastereoselectivity Between the Organomagnesium and Organolithium Reagents on Chiral <i>N</i>-<i>Tert</i>-Butylsulfinylaldimines for the Preparation of Chiral Amines
作者:Chinnapillai Rajendiran、Periyandi Nagarajan、A. Naidu、P. K. Dubey
DOI:10.1080/00397911.2014.909487
日期:2014.10.18
Abstract The asymmetric synthesis of both the enantiomer of chiral amines from the single chiral source of N-tert-butylsulfinylaldimines (3) by simply changing the organometallic reagents through diastereoselective addition. An efficient enantioselective synthesis of chiral amines including (S)-3-methyl-1-(2-piperidin-1-yl-phenyl)butyl amine (6a), a key intermediate to prepare antidiabetic drug repaglinide
A diastereoselective nucleophilic dichloromethylation between the N-tert-butanesulfinyl imines and dichloromethyllithium was developed. A series of 2-chloroaziridines with excellent yields and dr values were obtained via this nucleophilic addition and N-alkylation in one pot. On the basis of X-ray crystallography experiment, the predicting model for this diastereoselective transformation was provided
PROCESS AND INTERMEDIATES FOR MAKING TUBULYSIN ANALOGS
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20170362259A1
公开(公告)日:2017-12-21
An improved process for making a compound B of the structure
wherein n, R
1
, R
2
, and R
3
are as defined in the specification. Compound B can be used to make tubulysin analogs that are, in turn, useful as anti-cancer agents, particularly when deployed in an antibody-drug conjugate.
Provided are novel compounds of Formula (I):
pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.